(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 June 2011 (23.06.2011)

PCT

(10) International Publication Number
WO 2011/073339 A1

(51) International Patent Classification:
C07D 513/04 (2006.01) *A61K 31/429* (2006.01)
A61K 31/428 (2006.01) *A61P 25/18* (2006.01)

(21) International Application Number:
PCT/EP2010/069957

(22) International Filing Date:
16 December 2010 (16.12.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09179850.4 18 December 2009 (18.12.2009) EP
10193019.6 29 November 2010 (29.11.2010) EP

(71) Applicant *(for all designated States except US)*: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MACDONALD, Gregor, James** [GB/BE]; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **TRABANCO-SUÁREZ, Andrés, Avelino** [ES/ES]; Janssen-Cilag S.A., Calle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES). **CONDE-CEIDE, Susana** [ES/ES]; Janssen-Cilag S.A., Calle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES). **TRESADERN, Gary, John** [GB/ES]; Janssen-Cilag S.A., Calle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES). **BARTOLOMÉ-NEBREDA, José, Manuel** [ES/ES]; Janssen-Cilag S.A., Calle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES). **PASTOR-FERNÁNDEZ, Joaquin** [ES/ES]; C/Hierbabuena, Urbanización La Hacienda, Cobisa, E-45111 Toledo (ES).

(74) Common Representative: **JANSSEN PHARMACEUTICA NV**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *of inventorship (Rule 4.17(iv))*

[Continued on next page]

(54) Title: BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS



(I)

(57) Abstract: The present invention relates to novel bicyclic thiazoles of formula (I) which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 ("mGluR5") and which are useful for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which mGluR5 is involved.

WO 2011/073339 A1

Published:

— *with international search report (Art. 21(3))*